ATE488237T1 - Verfahren zur behandlung von abnormalem zellwachstum - Google Patents

Verfahren zur behandlung von abnormalem zellwachstum

Info

Publication number
ATE488237T1
ATE488237T1 AT06820997T AT06820997T ATE488237T1 AT E488237 T1 ATE488237 T1 AT E488237T1 AT 06820997 T AT06820997 T AT 06820997T AT 06820997 T AT06820997 T AT 06820997T AT E488237 T1 ATE488237 T1 AT E488237T1
Authority
AT
Austria
Prior art keywords
cell growth
abnormal cell
treating abnormal
treating
growth
Prior art date
Application number
AT06820997T
Other languages
English (en)
Inventor
James Gail Christensen
Yahong Zou
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE488237T1 publication Critical patent/ATE488237T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT06820997T 2005-12-05 2006-11-23 Verfahren zur behandlung von abnormalem zellwachstum ATE488237T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74276605P 2005-12-05 2005-12-05
US86463706P 2006-11-07 2006-11-07
PCT/IB2006/003397 WO2007066187A2 (en) 2005-12-05 2006-11-23 Method of treating abnormal cell growth

Publications (1)

Publication Number Publication Date
ATE488237T1 true ATE488237T1 (de) 2010-12-15

Family

ID=38123250

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06820997T ATE488237T1 (de) 2005-12-05 2006-11-23 Verfahren zur behandlung von abnormalem zellwachstum

Country Status (20)

Country Link
US (1) US7825137B2 (de)
EP (1) EP1959955B1 (de)
JP (1) JP4619346B2 (de)
KR (1) KR101026676B1 (de)
AR (1) AR056832A1 (de)
AT (1) ATE488237T1 (de)
AU (1) AU2006323027B2 (de)
BR (1) BRPI0619424B1 (de)
CA (1) CA2632286C (de)
CY (1) CY1110931T1 (de)
DE (1) DE602006018354D1 (de)
DK (1) DK1959955T3 (de)
IL (1) IL191471A (de)
NZ (1) NZ568654A (de)
PL (1) PL1959955T3 (de)
PT (1) PT1959955E (de)
RU (1) RU2384331C2 (de)
SI (1) SI1959955T1 (de)
TW (1) TWI321050B (de)
WO (1) WO2007066187A2 (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2373A (en) * 2004-08-26 2012-03-07 Pfizer Enantiomerically pure aminoheteroaryl compounds asprotein kinase inhibitors.
JP4077028B2 (ja) * 2005-08-24 2008-04-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 新規ピリジン誘導体およびピリミジン誘導体（３）
US8217057B2 (en) * 2005-12-05 2012-07-10 Pfizer Inc. Polymorphs of a c-MET/HGFR inhibitor
US20120208824A1 (en) 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
US8168383B2 (en) 2006-04-14 2012-05-01 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
US7700339B2 (en) 2006-04-14 2010-04-20 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
CA2661333C (en) * 2006-08-23 2014-08-05 Eisai R&D Management Co., Ltd. Salt of phenoxypyridine derivative or crystal thereof and process for producing the same
US7790885B2 (en) 2006-08-31 2010-09-07 Eisai R&D Management Co., Ltd. Process for preparing phenoxypyridine derivatives
JP2009132660A (ja) * 2007-11-30 2009-06-18 Eisai R & D Management Co Ltd 食道癌治療用組成物
DE102007061963A1 (de) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
US20090227556A1 (en) * 2008-01-31 2009-09-10 Eisai R&D Management Co., Ltd. Receptor tyrosine kinase inhibitors comprising pyridine and pyrimidine derivatives
WO2009103061A2 (en) * 2008-02-15 2009-08-20 The Children's Hospital Of Philadelphia Methods and compositions for identifying, diagnosing, and treating neuroblastoma
US20110206691A1 (en) * 2008-02-15 2011-08-25 Mosse Yael P Methods and Compositions for Treating Neuroblastoma
US20100311972A1 (en) * 2008-02-18 2010-12-09 Mitsuo Nagai Method for producing phenoxypyridine derivative
EP2143441A1 (de) * 2008-07-08 2010-01-13 Pierre Fabre Medicament Kombination aus einem c-MET-Antagonisten und einer Aminoheteroaryl-Verbindung zur Krebsbehandlung
CN101653607B (zh) * 2008-08-19 2013-02-13 鼎泓国际投资（香港）有限公司 含有肝细胞生长因子受体抑制剂和丝裂原细胞外激酶抑制剂的药物组合物及其用途
WO2010064300A1 (ja) * 2008-12-02 2010-06-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 食道癌治療用組成物
DE102009003954A1 (de) 2009-01-07 2010-07-08 Merck Patent Gmbh Pyridazinonderivate
DE102009004061A1 (de) 2009-01-08 2010-07-15 Merck Patent Gmbh Pyridazinonderivate
AU2010344973B2 (en) 2010-02-05 2016-06-16 Merck Patent Gmbh Hetaryl-[1,8]naphthyridine derivatives
EP2534156A1 (de) * 2010-02-11 2012-12-19 OSI Pharmaceuticals, LLC 7-aminofuropyridinderivate
US8916593B2 (en) 2010-05-04 2014-12-23 Pfizer Inc. Alkoxy-substituted 2-aminopyridines as ALK inhibitors
MX2012014776A (es) 2010-06-25 2013-01-29 Eisai R&D Man Co Ltd Agente antitumoral que emplea compuestos con efecto inhibidor de cinasas combinados.
AU2011276193B2 (en) 2010-07-05 2015-01-22 Merck Patent Gmbh Bipyridyl derivatives useful for the treatment of kinase - induced diseases
WO2012019132A2 (en) 2010-08-06 2012-02-09 Cell Signaling Technology, Inc. Anaplastic lymphoma kinase in kidney cancer
US9145390B2 (en) 2011-03-03 2015-09-29 Concert Pharmaceuticals, Inc. Derivatives of pyrazole-substituted amino-heteroaryl compounds
CA2829025A1 (en) * 2011-03-03 2012-09-07 Concert Pharmaceuticals, Inc. Derivatives of pyrazole-substituted amino-heteroaryl compounds
AU2012224979B2 (en) 2011-03-09 2017-01-19 Merck Patent Gmbh Pyrido [2, 3 - b] pyrazine derivatives and their therapeutical uses
US20140350050A1 (en) * 2011-09-21 2014-11-27 Teligene Ltd. Pyridine compounds as inhibitors of kinase
NZ627586A (en) 2012-01-31 2016-08-26 Daiichi Sankyo Co Ltd Pyridone derivatives
ES2621220T3 (es) 2012-03-06 2017-07-03 Pfizer Inc. Derivados macrocíclicos para el tratamiento de enfermedades proliferativas
WO2013148537A1 (en) * 2012-03-29 2013-10-03 Ning Xi Substituted spirobicyclic compounds and methods of use
DK2838998T3 (en) 2012-04-18 2018-01-15 Cell Signaling Technology Inc EGFR AND ROS1 IN CANCER
CN103509008A (zh) * 2012-06-22 2014-01-15 康瑟特制药公司 吡唑取代的氨基-杂芳基化合物的衍生物
WO2014020467A2 (en) 2012-07-30 2014-02-06 Fresenius Kabi Oncology Ltd Process for the preparation of pyrazole substituted aminoheteroaryl compounds
WO2014046730A1 (en) 2012-09-24 2014-03-27 Ventana Medical Systems, Inc. Method of identifying treatment responsive non-small cell lung cancer using anaplastic lymphoma kinase (alk) as a marker
JP6359020B6 (ja) * 2012-11-06 2018-08-15 シャンハイ フォチョン ファーマシューティカル カンパニー リミテッド Ａｌｋキナーゼ阻害剤
US9334239B2 (en) 2012-12-21 2016-05-10 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
EA201201654A1 (ru) * 2012-12-28 2014-06-30 Ооо "Эн.Си.Фарм" Противоопухолевое средство (варианты)
WO2014115169A2 (en) * 2013-01-24 2014-07-31 Hetero Research Foundation Crizotinib solid dispersion
HK1211235A1 (en) 2013-02-22 2016-05-20 霍夫曼-拉罗奇有限公司 Methods of treating cancer and preventing drug resistance
US20160022661A1 (en) * 2013-03-13 2016-01-28 Ratiopharm Gmbh Dosage Form Comprising Crizotinib
US10517861B2 (en) 2013-05-14 2019-12-31 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
JP6291179B2 (ja) * 2013-07-26 2018-03-14 関東化學株式会社 光学活性２級アルコールの製造方法
US20160214961A1 (en) * 2013-09-10 2016-07-28 Shilpa Medicare Limited Novel salts of crizotinib and their preparation
RU2550346C2 (ru) 2013-09-26 2015-05-10 Общество с ограниченной ответственностью "Отечественные Фармацевтические Технологии" ООО"ФармТех" Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний
WO2015069922A2 (en) 2013-11-06 2015-05-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Alk antibodies, conjugates, and chimeric antigen receptors, and their use
TWI723572B (zh) 2014-07-07 2021-04-01 日商第一三共股份有限公司 具有四氫吡喃基甲基之吡啶酮衍生物及其用途
CA2955676A1 (en) 2014-08-25 2016-03-03 Pfizer Inc. Combination of a pd-1 antagonist and an alk inhibitor for treating cancer
CN106660964B (zh) 2014-08-28 2021-09-03 卫材R&D管理有限公司 高纯度喹啉衍生物及其生产方法
PL3263106T3 (pl) 2015-02-25 2024-04-02 Eisai R&D Management Co., Ltd. Sposób tłumienia goryczy pochodnej chinoliny
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
ES2886107T3 (es) 2015-06-16 2021-12-16 Prism Biolab Co Ltd Antineoplásico
AU2016309356B2 (en) 2015-08-20 2021-06-24 Eisai R&D Management Co., Ltd. Tumor therapeutic agent
JP2018529719A (ja) 2015-09-30 2018-10-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ａｌｋ陰性がんを処置するためのｐｄ−１系結合アンタゴニストおよびａｌｋ阻害剤の組合せ
US12066428B2 (en) * 2015-11-20 2024-08-20 Agilent Technologies, Inc. Cell-substrate impedance monitoring of cancer cells
EA201892587A1 (ru) 2016-05-20 2019-04-30 Биохэйвен Фармасьютикал Холдинг Компани Лтд. Использование глутамат-модулирующих средств вместе с иммунотерапией для лечения рака
GB201616116D0 (en) * 2016-09-22 2016-11-09 Astrazeneca Ab Use of c-Met inhibitors to treat cancers harbouring MET mutations
MX380144B (es) 2017-02-08 2025-03-12 Eisai R&D Man Co Ltd Composicion farmaceutica de tratamiento de tumores.
CA3061888A1 (en) 2017-05-16 2018-11-22 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
CN108047231B (zh) * 2018-01-02 2020-02-11 江苏医药职业学院 [1,2,4]三嗪并[6,1-a]异吲哚化合物的盐酸盐及其应用
IT201800003875A1 (it) 2018-03-22 2019-09-22 Metis Prec Medicine Sb S R L Nuova combinazione di agenti terapeutici per il trattamento di un tumore e/o metastasi
EP4007585A4 (de) 2019-08-02 2023-11-08 OneHealthCompany, Inc. Behandlung von krebserkrankungen beim hund

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4725601A (en) 1985-06-04 1988-02-16 Fujisawa Pharmaceutical Co., Ltd. Certain imidazo[1,2-a]pyridines useful in the treatment of ulcers
GB9201693D0 (en) 1992-01-27 1992-03-11 Smithkline Beecham Intercredit Compounds
JPH07109260A (ja) 1993-10-12 1995-04-25 Fuji Photo Film Co Ltd ５−アミノ−２−ニトロピリジン誘導体及び２，５−ジアミノ−３−ヒドロキシピリジン誘導体の製造方法
ATE205483T1 (de) * 1995-03-30 2001-09-15 Pfizer Chinazolinderivate
SE9700661D0 (sv) 1997-02-25 1997-02-25 Astra Ab New compounds
SE9801526D0 (sv) 1998-04-29 1998-04-29 Astra Ab New compounds
GB9908410D0 (en) 1999-04-13 1999-06-09 Pfizer Ltd Pyridines
CN1348370A (zh) * 1999-04-15 2002-05-08 布里斯托尔-迈尔斯斯奎布公司 环状蛋白酪氨酸激酶抑制剂
CA2383546A1 (en) 1999-06-30 2001-01-04 William H. Parsons Src kinase inhibitor compounds
AU783915B2 (en) 2000-02-16 2005-12-22 Neurogen Corporation Substituted arylpyrazines
GB0101577D0 (en) 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
US6825198B2 (en) 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
US6992087B2 (en) 2001-11-21 2006-01-31 Pfizer Inc Substituted aryl 1,4-pyrazine derivatives
US7230098B2 (en) 2003-02-26 2007-06-12 Sugen, Inc. Aminoheteroaryl compounds as protein kinase inhibitors
EP1678147B1 (de) * 2003-09-15 2012-08-08 Lead Discovery Center GmbH Pharmazeutisch wirksame 4,6-disubstituierte aminopyrimidinderivate als modulatoren von proteinkinasen
US20080267905A1 (en) * 2004-05-05 2008-10-30 Celgene Corporation Methods and Compositions Using Selective Cytokine Inhibitory Drugs for Treatment and Management of Cancers and Other Diseases
JP2008510792A (ja) 2004-08-26 2008-04-10 ファイザー・インク タンパク質チロシンキナーゼ阻害剤としてのアミノヘテロアリール化合物
NZ552946A (en) * 2004-08-26 2010-09-30 Pfizer Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
AP2373A (en) * 2004-08-26 2012-03-07 Pfizer Enantiomerically pure aminoheteroaryl compounds asprotein kinase inhibitors.
US8217057B2 (en) * 2005-12-05 2012-07-10 Pfizer Inc. Polymorphs of a c-MET/HGFR inhibitor

Also Published As

Publication number Publication date
KR101026676B1 (ko) 2011-04-04
PL1959955T3 (pl) 2011-04-29
AU2006323027B2 (en) 2012-08-02
RU2384331C2 (ru) 2010-03-20
AU2006323027A1 (en) 2007-06-14
WO2007066187A2 (en) 2007-06-14
CA2632286C (en) 2011-11-15
JP4619346B2 (ja) 2011-01-26
SI1959955T1 (sl) 2011-02-28
DE602006018354D1 (de) 2010-12-30
US7825137B2 (en) 2010-11-02
WO2007066187A3 (en) 2008-01-17
PT1959955E (pt) 2011-01-04
TWI321050B (en) 2010-03-01
IL191471A (en) 2013-03-24
NZ568654A (en) 2012-02-24
AR056832A1 (es) 2007-10-24
CY1110931T1 (el) 2015-06-10
EP1959955A2 (de) 2008-08-27
TW200727899A (en) 2007-08-01
BRPI0619424B1 (pt) 2022-02-08
US20080300273A1 (en) 2008-12-04
RU2008122471A (ru) 2009-12-10
EP1959955B1 (de) 2010-11-17
JP2007153894A (ja) 2007-06-21
BRPI0619424A2 (pt) 2011-10-04
CA2632286A1 (en) 2007-06-14
HK1126121A1 (en) 2009-08-28
KR20080072965A (ko) 2008-08-07
DK1959955T3 (da) 2011-02-07
IL191471A0 (en) 2009-08-03

Similar Documents

Publication Publication Date Title
ATE488237T1 (de) Verfahren zur behandlung von abnormalem zellwachstum
EP2294183A4 (de) Mesenchymale stammzellen, zusammensetzungen und verfahren zur behandlung von herzgewebeschäden
DE602004021790D1 (de) Verfahren zur behandlung von parkinson-krankheit
ATE494780T1 (de) 2-cyanobenzolsulfonamidverbindungen zur behandlung von samen
DE602007006479D1 (de) Verfahren und vorrichtungen zur behandlung von mehreren bohrlochintervallen
EP1937143A4 (de) Verfahren zur beurteilung von harnstress-inkontinenz
DE602006007890D1 (de) Verfahren zur Optimierung von Kombikraftwerken/Kombiverarbeitungsanlagen
DE502006001614D1 (de) Verfahren zur herstellung von 1-alkyl-3-phenyluracilen
ATE474602T1 (de) Verfahren zur behandlung von hiv-infektion
EP2049140A4 (de) Kit und verfahren zur behandlung der bandscheiben
EP2278979A4 (de) Verfahren zur behandlung von pneumokoniose mit oligodesoxynukleotiden
EP2039757A4 (de) Verfahren zur zell- oder gewebekultivierung
EP1948178A4 (de) Verfahren zur behandlung von vorhofflimmern mit p38-inhibitor-verbindungen
EP2046366A4 (de) Verfahren zur behandlung von altersbedingter makuladegeneration
EP2099446A4 (de) Verfahren zur behandlung von entzündlicher darmerkrankung
ATE544341T1 (de) Verfahren zur verbesserung des nematoden toleranten bzw. -resistenten pflanzenwachstums
EP2037736A4 (de) Verfahren zur behandlung von zystennierenerkrankungen
EP1948675A4 (de) Verfahren und zusammensetzungen zur behandlung von marfan-syndrom und verwandten erkrankungen
EP2120994A4 (de) Verfahren und zusammensetzungen zur behandlung hypoglykämischer zustände
EP1848834A4 (de) Verfahren zur behandlung von kupferhaltigen materialien
ZA200804777B (en) Method of treating abnormal cell growth
DE502005010287D1 (de) Verfahren zur hydrocyanierung
EP1960416A4 (de) Verfahren zur aufreinigung von chenodesoxycholsäure
ATE394369T1 (de) Verfahren zur aufreinigung von mesotrion
EP1845971A4 (de) Verfahren zur behandlung von zellschäden

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1959955

Country of ref document: EP